Purpose and goal
The project aims to validate and optimize the non-invasive cardiac therapy, which uses ultrasound to stimulate new blood vessel formation in patients with refractory angina. The goal is to ensure a safe, efficient and targeted treatment through testing with a realistic ultrasound phantom.
Expected effects and result
The project is expected to deliver verified safety, precision and reproducibility for the NEOWAVE therapy, strengthening regulatory readiness for clinical studies. Validation in a phantom environment also reduces the need for animal testing, streamlining development and strengthening ethical sustainability. The results will contribute to CE marking, commercialization and improved patient quality of life.
Planned approach and implementation
The project is being implemented in three work packages: (1) requirements specification and project planning, (2) ultrasound phantom construction and experimental design, and (3) validation testing to confirm accuracy and safety. The work is led by CSW Therapeutics with support from clinical, technical, and regulatory experts.
The project description has been provided by the project members themselves and the text has not been looked at by our editors.
